FULGENT GENETICS, INC. (NASDAQ:FLGT) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
Results of Operations and Financial Condition.
FULGENT GENETICS, INC. (NASDAQ:FLGT) Files An 8-K Results of Operations and Financial Condition
On August7, 2017, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June30, 2017. A copy of the Company’s press release containing this information is being furnished as Exhibit99.1 to this Current Report on Form8-K.
In accordance with General Instruction B.2 of Form8-K, the information in this Item 2.02, including Exhibit99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|
Item 2.02. |
Financial Statements and Exhibits. |
|
Exhibit No. |
Description |
|
99.1 |
Press Release of Fulgent Genetics, Inc., dated August7, 2017 |
Fulgent Genetics, Inc. ExhibitEX-99.1 2 flgt-ex991_15.htm EX-99.1 flgt-ex991_15.htm Exhibit 99.1 Fulgent Genetics Reports Second Quarter 2017 Financial Results • Revenue grows 17% year over year to $4.6 Million • GAAP Loss of $25,…To view the full exhibit click here
About FULGENT GENETICS, INC. (NASDAQ:FLGT)
Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company’s test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company’s gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.
